Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.

Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SE. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.

View in: PubMed